The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
 
 
 
 

Olsalazine in ankylosing spondylitis: a pilot study.

OBJECTIVE. To test the safety and efficacy of olsalazine in men with ankylosing spondylitis (AS) unresponsive to nonsteroidal antiinflammatory drugs and physiotherapy. METHODS. Four patients, including 2 who had not responded to sulfasalazine (SASP) and one who did not tolerate SASP, were treated with olsalazine, up to 3 g/dl for 24 weeks. RESULTS. One patient discontinued olsalazine due to diarrhea at 1 g/day. The other 3 experienced improvement in global spine self assessment by visual analog scale (VAS), 2 of 3 patients, spinal pain (VAS, 3 of 3), night pain (3 of 3), tender joint count (3 of 3) and enthesis score (3 of 3). Changes in Schober's test and chest expansion were minor. Erythrocyte sedimentation rate and C-reactive protein were normal. Loose stools were the only adverse effects observed. CONCLUSION. Olsalazine appears to be well tolerated and effective in men with AS. Further study of olsalazine and direct comparison with SASP in this population may illuminate mechanisms of drug action and add a new therapeutic option.[1]

References

  1. Olsalazine in ankylosing spondylitis: a pilot study. Chapman, C.M., Zwillich, S.H. J. Rheumatol. (1994) [Pubmed]
 
WikiGenes - Universities